<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="vaccines-07-00045-t001" orientation="portrait" position="float">
 <object-id pub-id-type="pii">vaccines-07-00045-t001_Table 1</object-id>
 <label>Table 1</label>
 <caption>
  <p>Summary and examples of computational influenza universal vaccine design.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Approach</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Conceptual Design</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Evidence-Level</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Advantages</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disadvantages</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Examples</bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Consensus-based optimized approach</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <xref ref-type="fig" rid="vaccines-07-00045-f002">Figure 2</xref>A
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-clinical</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Efficiently generate a potentially full profile of conserved immunogenicity in viral genome;
     <break/>(2) Induce broad HA inhibition antibody titers that are cross-reactive with diverse strains within the same subtype;
     <break/>(3) Neutralize the receptor binding sites to prevent influenza disease with a clear path towards clinical proof of correlation for protective efficacy in humans
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Biased viral samples may not generate consensus sequences that represent full profile of conserved immunogenicity;
     <break/>(2) Large efforts on surveillance data required
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-clinical tests on H1, H3 and H5 HA [
     <xref rid="B28-vaccines-07-00045" ref-type="bibr">28</xref>,
     <xref rid="B41-vaccines-07-00045" ref-type="bibr">41</xref>,
     <xref rid="B42-vaccines-07-00045" ref-type="bibr">42</xref>,
     <xref rid="B43-vaccines-07-00045" ref-type="bibr">43</xref>,
     <xref rid="B45-vaccines-07-00045" ref-type="bibr">45</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Ancestral sequence reconstruction</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <xref ref-type="fig" rid="vaccines-07-00045-f002">Figure 2</xref>B
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-clinical</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Induce broad cross-reactive protection within highly diverse influenza subtype
     <break/>(2) Account for sampling bias and the variability of substitution rates among sites;
     <break/>(3) Potentially avoid the detrimental effects of antigenic drift with ancestral sequences;
     <break/>(4) Incorporate protein functional and structural domains
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) More sophisticated and advanced models to incorporate protein domains are still under development;
     <break/>(2) Experimental data on protein function is needed
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-clinical tests on ancestral sequence of H5N1 HA and NA [
     <xref rid="B44-vaccines-07-00045" ref-type="bibr">44</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Immunomics</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <xref ref-type="fig" rid="vaccines-07-00045-f002">Figure 2</xref>C
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-clinical &amp; Clinical</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Account for the heterogeneity of the major histocompatibility complex (MHC) in host;
     <break/>(2) Protections and viral clearance from T-cell response has been distinctively tested
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Indirect estimation on epitope affinity to MHC;
     <break/>(2) To keep conformational epitopes to be function when designed into vaccine can be challenge
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FP-01.1
     <break/>Flu-v
     <break/>Multimeric-001
     <break/>See 
     <xref rid="vaccines-07-00045-t002" ref-type="table">Table 2</xref> for details
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
